Randomized, open-labelled study evaluating the antiviral efficacy, safety, and tolerability of continuing laminudine therapy or switching to entecavir in subjects with chronic hepatitis B with detectable HBV DNA(HBV DNA ≥60 IU/mL by PCR) with on lamivudine for at least 6 months: Interim analysis at 48 weeks

상세 보기

제목: Randomized, open-labelled study evaluating the antiviral efficacy, safety, and tolerability of continuing laminudine therapy or switching to entecavir in subjects with chronic hepatitis B with detectable HBV DNA(HBV DNA ≥60 IU/mL by PCR) with on lamivudine for at least 6 months: Interim analysis at 48 weeks